rethinkTHC Search
Menu
Study breakdown

Cannabis use neither helped nor hurt opioid treatment outcomes in people with opioid use disorder

Meta AnalysisHigh evidence
The takeaway

A meta-analysis of 10 studies with 8,367 participants found no significant association between cannabis use and return to non-medical opioid use during opioid use disorder treatment.

People interested in opioid use disorder treatment, harm reduction, and cannabis policy in addiction medicine.

OR 1.00: cannabis had zero association with opioid relapse during treatment

What the researchers found

The pooled odds ratio was 1.00 (95% CI: 0.97-1.04, p=.98), indicating no association between cannabis use and non-medical opioid use during OUD treatment. This null finding held across treatment types (methadone, buprenorphine, naltrexone). Average follow-up was 9.7 months.

Why it matters

Some treatment programs require cannabis abstinence for opioid use disorder medication. This meta-analysis found no evidence that cannabis use worsens opioid treatment outcomes, challenging the rationale for mandatory cannabis abstinence policies.

The numbers in context

10 studies, 8,367 participants. 38% female. Pooled OR: 1.00 (95% CI: 0.97-1.04). Average follow-up: 9.7 months. Treatment: methadone 76.3%, buprenorphine 21.3%, naltrexone 2.4%. Moderate heterogeneity.

How the study worked

Systematic review and meta-analysis of 10 longitudinal studies found across multiple databases. Random-effects model with restricted maximum likelihood. Sensitivity analysis by OUD treatment modality. 8,367 participants (38% female), mostly receiving methadone (76.3%).

What this study cannot tell us

Moderate heterogeneity and evidence of publication bias. Mostly methadone patients (76.3%), limiting generalizability to other medications. Cannot distinguish between different cannabis use patterns (frequency, quantity, method). Does not assess cannabis for OUD treatment, only concurrent use.

How to read the evidence

High-quality meta-analysis of longitudinal studies with large pooled sample. Limited by moderate heterogeneity, publication bias, and heavy methadone representation.

When this study was published

Published in 2024 in the American Journal of Drug and Alcohol Abuse, searching through April 2023.

The bigger picture

The question of whether cannabis helps or hinders opioid recovery is politically charged. This meta-analysis provides the most definitive answer yet: neither. This supports individualized approaches rather than blanket policies requiring cannabis abstinence for OUD treatment.

Questions still open

  • Should cannabis abstinence requirements be removed from OUD treatment programs? Would heavy versus occasional cannabis use show different associations? Could certain cannabis use patterns actually improve OUD treatment adherence through stress reduction?

Common questions

Does cannabis use interfere with opioid addiction treatment?
This meta-analysis of over 8,000 patients found no association between cannabis use and return to non-medical opioid use during treatment. The odds ratio was exactly 1.00, meaning cannabis use neither helped nor hurt.
Should opioid treatment programs require cannabis abstinence?
The authors suggest these findings challenge the requirement of cannabis abstinence to maintain OUD treatment, arguing for individualized approaches rather than blanket policies that could prevent people from accessing life-saving medications.

Read the original research

The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.

The American journal of drug and alcohol abuse, 50(1), 12-26

Citation

Costa, Gabriel P A; Nunes, Julio C; Heringer, Daniel L; Anand, Akhil; De Aquino, Joao P. (2024). The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.. The American journal of drug and alcohol abuse, 50(1), 12-26. https://doi.org/10.1080/00952990.2023.2287406

Explore the wider topic